-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11

Benzinga·12/17/2025 12:44:23
Listen to the news
HC Wainwright & Co. analyst Matthew Keller maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and raises the price target from $6 to $11.